Form 4: Theriva Biologics Director Acquires 75,000 Stock Options

Jeffrey J. Kraws, a Director at Theriva Biologics, Inc., acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months.

Summary

• Jeffrey J. Kraws, a Director of Theriva Biologics, Inc. (TOVX), acquired 75,000 stock options.
• The transaction date for this acquisition was January 5, 2026.
• Each stock option has an exercise price of $0.241.
• The options vest pro rata on a monthly basis over 12 months, commencing February 1, 2026.
• The expiration date for these stock options is January 4, 2033.
• Following this transaction, Mr. Kraws beneficially owns 75,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating management's confidence in the company's future performance. However, it is a routine compensation event rather than a direct open-market purchase, hence a moderately positive score.

Positives

• A Director, Jeffrey J. Kraws, acquired 75,000 stock options, which can signal confidence in the company's future prospects.
• The exercise price of $0.241 per option suggests a belief in the stock's potential to rise above this value.

Negatives

• No specific negative information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The acquisition of stock options with a vesting schedule over 12 months indicates a future commitment and potential for increased beneficial ownership of common stock by the director upon exercise. The long expiration date of January 4, 2033, provides a significant window for the options to become in-the-money.

Industry Context

This is a standard insider transaction report (Form 4) indicating a director's acquisition of equity-based compensation. Such transactions are common in the biotechnology industry, where executive compensation often includes stock options to align management interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director may be perceived as a positive signal of confidence in the company's future, potentially influencing investor sentiment.

Next Steps

• The stock options will vest pro rata on a monthly basis over the next 12 months, starting February 1, 2026.
• Upon vesting, the director will have the right to exercise these options at $0.241 per share until January 4, 2033.

Key Dates

Keywords

Theriva Biologics, TOVX, Stock Options, Insider Transaction, Form 4, Director, Equity Acquisition, Beneficial Ownership